TY - JOUR
T1 - The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers
AU - Tsai, Ming Han
AU - Lin, Xiaochen
AU - Shumilov, Anatoliy
AU - Bernhardt, Katharina
AU - Feederle, Regina
AU - Poirey, Remy
AU - Kopp-Schneider, Annette
AU - Pereira, Bruno
AU - Almeida, Raquel
AU - Delecluse, Henri Jacques
N1 - Funding Information:
This work was supported by Institut National de la Sant? et de la Recherche M?dicale (Inserm) (Unit U1074) and German Cancer Research Center (DKFZ) (Unit F100).
PY - 2017
Y1 - 2017
N2 - The Epstein-Barr virus (EBV) is etiologically associated with the development of multiple types of tumors, but it is unclear whether this diversity is due to infection with different EBV strains. We report a comparative characterization of SNU719, GP202, and YCCEL1, three EBV strains that were isolated from gastric carcinomas, M81, a virus isolated in a nasopharyngeal carcinoma and several well-characterized laboratory type A strains. We found that B95-8, Akata and GP202 induced cell growth more efficiently than YCCEL1, SNU719 and M81 and this correlated positively with the expression levels of the viral BHRF1 miRNAs. In infected B cells, all strains except Akata and B95-8 induced lytic replication, a risk factor for carcinoma development, although less efficiently than M81. The panel of viruses induced tumors in immunocompromised mice with variable speed and efficacy that did not strictly mirror their in vitro characteristics, suggesting that additional parameters play an important role. We found that YCCEL1 and M81 infected primary epithelial cells, gastric carcinoma cells and gastric spheroids more efficiently than Akata or B95-8. Reciprocally, Akata and B95-8 had a stronger tropism for B cells than YCCEL1 or M81. These data suggest that different EBV strains will induce the development of lymphoid tumors with variable efficacy in immunocompromised patients and that there is a parallel between the cell tropism of the viral strains and the lineage of the tumors they induce. Thus, EBV strains can be endowed with properties that will influence their transforming abilities and the type of tumor they induce.
AB - The Epstein-Barr virus (EBV) is etiologically associated with the development of multiple types of tumors, but it is unclear whether this diversity is due to infection with different EBV strains. We report a comparative characterization of SNU719, GP202, and YCCEL1, three EBV strains that were isolated from gastric carcinomas, M81, a virus isolated in a nasopharyngeal carcinoma and several well-characterized laboratory type A strains. We found that B95-8, Akata and GP202 induced cell growth more efficiently than YCCEL1, SNU719 and M81 and this correlated positively with the expression levels of the viral BHRF1 miRNAs. In infected B cells, all strains except Akata and B95-8 induced lytic replication, a risk factor for carcinoma development, although less efficiently than M81. The panel of viruses induced tumors in immunocompromised mice with variable speed and efficacy that did not strictly mirror their in vitro characteristics, suggesting that additional parameters play an important role. We found that YCCEL1 and M81 infected primary epithelial cells, gastric carcinoma cells and gastric spheroids more efficiently than Akata or B95-8. Reciprocally, Akata and B95-8 had a stronger tropism for B cells than YCCEL1 or M81. These data suggest that different EBV strains will induce the development of lymphoid tumors with variable efficacy in immunocompromised patients and that there is a parallel between the cell tropism of the viral strains and the lineage of the tumors they induce. Thus, EBV strains can be endowed with properties that will influence their transforming abilities and the type of tumor they induce.
KW - Carcinoma and lymphoma
KW - Epstein-Barr virus strains
KW - Host-virus interactions
KW - Human tumor viruses
KW - Viral infection and transformation
UR - http://www.scopus.com/inward/record.url?scp=85012012695&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.14380
DO - 10.18632/oncotarget.14380
M3 - Article
C2 - 28052012
AN - SCOPUS:85012012695
SN - 1949-2553
VL - 8
SP - 10238
EP - 10254
JO - Oncotarget
JF - Oncotarget
IS - 6
ER -